Adrenomed AG takes part in four upcoming conferences

Hennigsdorf (Germany), August 13, 2019 – Adrenomed AG, the vascular integrity company, announced today its participation at four upcoming conferences in Europe. Adrenomed representatives will be available for networking and one-to-one meetings at the following events:

Weimar Sepsis Update – Symposium
September 11^th – 13^th, 2019, Congress Centrum Neue Weimarhalle, Weimar, Germany
Adrenomed will co-host the lunch symposium “Beyond Standard of Care – New Perspectives on Vascular Integrity in Shock” on September 13^th, 12:00 – 13:30 CET.
https://www.sepsis-gesellschaft.de/kongress/

19^th Annual Biotech in Europe Forum (Sachs Conference)
September 25^th – 26^th, 2019, Congress Center Basel, Switzerland
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will participate in the“Platform Technologies & Novel Therapeutics Panel” on September 25^th, 10:45 CET.
https://www.sachsforum.com/bef19-about.html

European Business Development Conference (EBDC)
September 25^th – 26^th, 2019, Deutsches Krebsforschungszentrum (DKFZ), Heidelberg, Germany
Dr. Frauke Hein, Chief Business Officer of Adrenomed, will give a “Spotlight Talk on Sepsis” on September 26^th, 12:00 CET.
https://www.biodeutschland.org/de/european-business-development-conference-2019.html

32^nd European Society of Intensive Care Medicine (ESICM) LIVES
September 28^th – October 2^nd, 2019, CityCube, Berlin, Germany
Prof. Dr. Peter Pickkers, Radboud University, Department of Intensive Care, Nijmegen, The Netherlands, will give a presentation about “Adrenomedullin in sepsis, effect of the non-inhibitory antibody Adrecizumab”, session “Innovation in sepsis treatment”, on October 1^st, 16:20 CET, room Stockholm.
https://www.esicm.org/events/32nd-annual-congress-berlin/

About Adrenomed
Adrenomed AG is a German privately-financed, clinical stage biopharmaceutical company. Adrenomed´s mission is to rescue vascular integrity in order to save the lives of critically ill patients with limited treatment options. Founded in 2009 by a management team with decades of in-depth experience in sepsis and deep knowledge in diagnostics and drug development, the Company’s lead product candidate Adrecizumab is a clinical-stage, first-in-class monoclonal antibody. Adrecizumab targets the vasoprotective peptide Adrenomedullin, an essential regulator of vascular integrity. Adrecizumab is currently under clinical evaluation in a biomarker-guided, double-blinded, placebo-controlled, randomized, multicenter proof-of-concept Phase II study with 300 patients suffering septic shock. Excellent safety and tolerability were demonstrated in two Phase I trials. www.adrenomed.com